Bolt Biotherapeutics, Inc. Investment Income, Net
Bolt Biotherapeutics, Inc. (BOLT) reported Investment Income, Net of $178.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Income Statement › Other Income
us-gaap:InvestmentIncomeNet · last filed 2026-08-11
- Bolt Biotherapeutics, Inc. investment income, net for the quarter ending 2026-06-30 was $178.00K, a 70.28% decline year-over-year.
- Bolt Biotherapeutics, Inc. investment income, net for the quarter ending 2026-03-31 was $276.00K, a 73.79% decline year-over-year.
- Bolt Biotherapeutics, Inc. investment income, net for the quarter ending 2025-12-31 was $367.00K, a 62.55% decline year-over-year.
- Bolt Biotherapeutics, Inc. investment income, net for the quarter ending 2025-09-30 was $477.00K, a 62.35% decline year-over-year.
- Bolt Biotherapeutics, Inc. investment income, net for fiscal 2025 was $2.50M, a 52.50% decline from fiscal 2024.
- Bolt Biotherapeutics, Inc. investment income, net for fiscal 2024 was $5.25M, a 24.92% decline from fiscal 2023.
- Bolt Biotherapeutics, Inc. investment income, net for fiscal 2023 was $7.00M, a 214.84% increase from fiscal 2022.
- Bolt Biotherapeutics, Inc. investment income, net for fiscal 2022 was $2.22M, a 691.10% increase from fiscal 2021.
| Period end | Investment Income, Net 3 month | Investment Income, Net 6 month | Investment Income, Net 9 month | Investment Income, Net 12 month |
|---|---|---|---|---|
| 2026-06-30 | $178.00K 10-Q · filed 2026-08-11 | $454.00K 10-Q · filed 2026-08-11 | $821.00K derived: sum of 3 quarters · filed 2026-08-11 | $1.30M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $276.00K 10-Q · filed 2026-05-12 | $643.00K derived: sum of 2 quarters · filed 2026-05-12 | $1.12M derived: sum of 3 quarters · filed 2026-05-12 | $1.72M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $367.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $844.00K derived: sum of 2 quarters · filed 2026-03-12 | $1.44M derived: sum of 3 quarters · filed 2026-08-11 | $2.50M 10-K · filed 2026-03-12 |
| 2025-09-30 | $477.00K 10-Q · filed 2025-11-12 | $1.08M derived: sum of 2 quarters · filed 2026-08-11 | $2.13M 10-Q · filed 2025-11-12 | $3.11M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $599.00K 10-Q · filed 2026-08-11 | $1.65M 10-Q · filed 2026-08-11 | $2.63M derived: sum of 3 quarters · filed 2026-08-11 | $3.90M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $1.05M 10-Q · filed 2026-05-12 | $2.03M derived: sum of 2 quarters · filed 2026-05-12 | $3.30M derived: sum of 3 quarters · filed 2026-05-12 | $4.70M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $980.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $2.25M derived: sum of 2 quarters · filed 2026-03-12 | $3.65M derived: sum of 3 quarters · filed 2026-03-12 | $5.25M 10-K · filed 2026-03-12 |
| 2024-09-30 | $1.27M 10-Q · filed 2025-11-12 | $2.67M derived: sum of 2 quarters · filed 2025-11-12 | $4.28M 10-Q · filed 2025-11-12 | $6.14M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $1.40M 10-Q · filed 2025-08-14 | $3.01M 10-Q · filed 2025-08-14 | $4.87M derived: sum of 3 quarters · filed 2025-08-14 | $6.80M derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | $1.61M 10-Q · filed 2025-05-12 | $3.47M derived: sum of 2 quarters · filed 2025-05-12 | $5.39M derived: sum of 3 quarters · filed 2025-05-12 | $7.17M derived: sum of 4 quarters · filed 2025-05-12 |
| 2023-12-31 | $1.86M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-24 | $3.79M derived: sum of 2 quarters · filed 2025-03-24 | $5.56M derived: sum of 3 quarters · filed 2025-03-24 | $7.00M 10-K · filed 2025-03-24 |
| 2023-09-30 | $1.93M 10-Q · filed 2024-11-12 | $3.70M derived: sum of 2 quarters · filed 2024-11-12 | $5.14M 10-Q · filed 2024-11-12 | $6.18M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | $1.77M 10-Q · filed 2024-08-13 | $3.21M 10-Q · filed 2024-08-13 | $4.25M derived: sum of 3 quarters · filed 2024-08-13 | $4.84M derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | $1.44M 10-Q · filed 2024-05-14 | $2.48M derived: sum of 2 quarters · filed 2024-05-14 | $3.06M derived: sum of 3 quarters · filed 2024-05-14 | $3.46M derived: sum of 4 quarters · filed 2024-05-14 |
| 2022-12-31 | $1.04M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | $1.63M derived: sum of 2 quarters · filed 2024-03-21 | $2.02M derived: sum of 3 quarters · filed 2024-03-21 | $2.22M 10-K · filed 2024-03-21 |
| 2022-09-30 | $587.00K 10-Q · filed 2023-11-09 | $982.00K derived: sum of 2 quarters · filed 2023-11-09 | $1.18M 10-Q · filed 2023-11-09 | $1.10M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $395.00K 10-Q · filed 2023-08-07 | $593.00K 10-Q · filed 2023-08-07 | $511.00K derived: sum of 3 quarters · filed 2023-08-07 | $642.00K derived: sum of 4 quarters · filed 2023-08-07 |
| 2022-03-31 | $198.00K 10-Q · filed 2023-05-11 | $116.00K derived: sum of 2 quarters · filed 2023-05-11 | $247.00K derived: sum of 3 quarters · filed 2023-05-11 | $423.00K derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | -$82.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-29 | $49.00K derived: sum of 2 quarters · filed 2023-03-29 | $225.00K derived: sum of 3 quarters · filed 2023-03-29 | $281.00K 10-K · filed 2023-03-29 |
| 2021-09-30 | $131.00K 10-Q · filed 2022-11-10 | $307.00K derived: sum of 2 quarters · filed 2022-11-10 | $363.00K 10-Q · filed 2022-11-10 | $375.00K derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | $176.00K 10-Q · filed 2022-08-10 | $232.00K 10-Q · filed 2022-08-10 | $244.00K derived: sum of 3 quarters · filed 2022-08-10 | $268.00K derived: sum of 4 quarters · filed 2022-08-10 |
| 2021-03-31 | $56.00K 10-Q · filed 2022-05-12 | $68.00K derived: sum of 2 quarters · filed 2022-05-12 | $92.00K derived: sum of 3 quarters · filed 2022-05-12 | $143.00K derived: sum of 4 quarters · filed 2022-05-12 |
| 2020-12-31 | $12.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-30 | $36.00K derived: sum of 2 quarters · filed 2022-03-30 | $87.00K derived: sum of 3 quarters · filed 2022-03-30 | $199.00K 10-K · filed 2022-03-30 |
| 2020-09-30 | $24.00K 10-Q · filed 2021-11-09 | $75.00K derived: sum of 2 quarters · filed 2021-11-09 | $187.00K 10-Q · filed 2021-11-09 | |
| 2020-06-30 | $51.00K 10-Q · filed 2021-08-12 | $163.00K 10-Q · filed 2021-08-12 | ||
| 2020-03-31 | $112.00K 10-Q · filed 2021-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |